Diabetes
Conditions
Brief summary
The goal of this clinical trial is to learn about inour study aimed to evaluate serum lipid profiles of T2DM patients before and after Chiglitazar Sodium administration. The main question\[s\] it aims to answer are: * Quantitative lipidomics information enables in-depth analysis of lipids and can reveal Chiglitazar Sodium-specific lipid metabolic patterns, thereby strengthening lipidomics as a promising tool for exploring the molecular mechanisms of T2DM. * It can also be applied to other T2DM lipidomics studies to better understand lipid metabolism patterns and integration with other omics measures.
Detailed description
Chiglitazar Sodium for lipid profile abnormalities and its associated effective lipid molecular biomarkers have never been studied in patients with T2DM. Therefore, our study aimed to evaluate serum lipid profiles of T2DM patients before and after Chiglitazar Sodium administration using ultra-high performance liquid chromatography-Tandem quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS). For completeness, we also evaluated the effects of Chiglitazar Sodium treatment on metabolic markers associated with T2DM and its association with lipidomic changes.
Interventions
In patients with type 2 diabetes mellitus (T2DM), on the basis of one or two oral hypoglycemic agents combination with Chiglitazar sodium.
Sponsors
Yufan Wang
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with type 2 diabetes (T2DM) WHO meet the diagnostic criteria for diabetes issued by the World Health Organization (WHO) in 1999; 2. Male or female patients aged ≥18, ≤70 years; 3. BMI≥18.5 Kg/m2, \< 35 Kg/m2; 4. Hemoglobin a1C (HbA1C) ≥7.5%; ≤10.5%; 5. Triglyceride ≤500 mg /dL (5.65 mmol/L) (if the researchers judge that the transient increase caused by diet, etc., can be repeated detection) 6. Total cholesterol (TC) ≤250mg/dl (6.45mmol/L) 7. T2DM patients who are taking one or two kinds of oral hypoglycemic drugs with fixed dose ≥2 months and uncontrolled blood glucose. 8. Voluntarily sign informed consent and agree to enter the trial group.
Exclusion criteria
1. Type 1 diabetes or other specific type of diabetes 2. Fasting blood glucose (FPG) \> 13.3 mmol/L (240 mg/dL); 3. Triglyceride (TG) \> 500 mg /dL (5.65 mmol/L); 4. Total cholesterol (TC) > 250mg/dl (> 6.45mmol/L); 5. Refractory hypertension \[that is, on the basis of improving the lifestyle, the blood pressure is still not up to standard after 1 month of applying a reasonably tolerable amount of 3 or more antihypertensive drugs (including diuretics), or the blood pressure can be effectively controlled by taking 4 or more antihypertensive drugs; 6. Taking fibrates, statins, thiazolidinediones, insulin drugs; 7. A clear diagnosis of severe osteoporosis or any other known bone disease; 8. A history of diabetic ketoacidosis, diabetic hyperglycemia hyperosmolar syndrome, lactic acidosis and other acute complications of diabetes; 9. Severe microvascular complications (proliferative retinopathy; Urinary albumin/creatinine ratio > 300 mg/g; Marked peripheral neuropathy, etc.); 10. The New York Heart Association (NYHA) defines congestive heart failure as grade III or IV; 11. Significant liver and kidney dysfunction and systemic disease (significant liver dysfunction is defined as AST> 2.5 times the upper limit of normal and/or ALT> 2.5 times the upper limit of normal and/or total bilirubin > 1.5 times the upper limit of normal value; Renal dysfunction was defined as moderate to severe renal insufficiency (eGFR<60 ml/ (min\*1.73m2)); 12. Pregnant or lactating women, women of childbearing age who are unable or unwilling to take adequate contraception; 13. Participating in a clinical trial of another drug or medical device in or within 3 months prior to screening; 14. The investigator considers it inappropriate to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HbA1c | 12 weeks of treatment | Change in HbA1c from baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum lipid profile | 12 weeks of treatment | Changes from baseline in sphingomyelin (SMs), ceramide (CER), lysophosphatidylcholine (LPC), phosphatidylethanolamine (PEs), lysophosphatidylethanolamine (LPEs), and phosphatidylcholine (PC) |
Countries
China
Outcome results
None listed